Li Han
Role not yet determined Is this you? Add your title
Also affiliated: University of Nebraska–Lincoln (2023); Fujian Medical University (2023–2025); Pennsylvania State University (2023); Howard Hughes Medical Institute (2025); North China University of Science and Technology (2025); University of Shanghai for Science and Technology (2022); University of Electronic Science and Technology of China (2024–2026); Shandong University (2018); Sun Yat-sen University (2017–2020); Linyi University (2006); China Pharmaceutical University (2012–2016); University of Pittsburgh (2008); Hunan Normal University (2025); Shanxi Medical University (2021); Xuzhou Medical College (2015–2024); Yanbian University (2021); Shanghai Jiao Tong University (2011); Capital Medical University (2021–2026); Chinese Center For Disease Control and Prevention (2024); China Medical University (2020–2023); Dalian Medical University (2019–2020); Jilin University (2018); Peking University (2003–2024); Huazhong Agricultural University (2009–2020); Sichuan University (2016); Southwest Forestry University (2020); University of Michigan (2023); Beijing Chao-Yang Hospital, Capital Medical University (2021); University of Florida Health (2023–2024); WellStar Kennestone Hospital (2025); XinHua Hospital (2011); Beijing Jishuitan Hospital (2026); Southwest Medical University (2024); University of Florida (2023–2024); Wuhan University (2012); Zhengzhou University (2011–2012); University of Chicago (2025); West China Hospital of Sichuan University (2016); People 's Hospital of Jilin Province (2014); Central Arkansas Veterans Healthcare System (2004–2016); Zhongda Hospital Southeast University (2017–2021); City of Hope (2019); Weifang People's Hospital (2018); Nanyang Institute of Technology (2014–2026); Shandong Provincial Hospital (2018); Affiliated Hospital of Qingdao University (2017–2018); Sichuan Cancer Hospital (2024–2026); People's Hospital of Xinjiang Uygur Autonomous Region (2019); Heilongjiang Bayi Agricultural University (2025); Lanzhou University Second Hospital (2018–2022); The Affiliated Yongchuan Hospital of Chongqing Medical University (2022–2024); Peking University First Hospital (2003); Yanbian University Hospital (2021); Shanghai University of Medicine and Health Sciences (2019–2025); National Institute for Viral Disease Control and Prevention (2024); Second Affiliated Hospital of Jilin University (2018); Fujian Provincial Hospital (2023); Sun Yat-sen University Cancer Center (2017–2021); Baoji City Central Hospital (2024); Liaocheng People's Hospital (2025); Center for Life Sciences (2024); Affiliated Hospital of Jining Medical University (2021–2025); First Affiliated Hospital of Jinan University (2021); Shandong First Medical University (2021); State Key Laboratory of Oncology in South China (2017–2020); Key Laboratory of Computing and Stochastic Mathematics (Ministry of Education) (2025); Tianjin Medical University (2023); Ocean University of China (2006); Southeast University (2017); Fuzhou University (2025); China Medical University (2020–2023); Guangzhou Medical University (2021–2026); Osmania Medical College (2024)
Upstream record may be merged OpenAlex, the source of these figures, lists 74 institutions in 4 countries for this author record — a pattern that usually means it combines several researchers with similar names. The totals above may include work by other people.
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Li Han's research focuses on cancer treatment, particularly exploring the efficacy of combination therapies and novel therapeutic targets. Han has investigated the use of sintilimab in combination with chemotherapy as a first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma, as documented in the ORIENT-16 phase III study. Additionally, Han's work includes studies on transarterial chemoembolization combined with lenvatinib and PD-1 inhibitors for hepatocellular carcinoma, with research aiming to predict early treatment response and overall prognosis in patients with portal vein tumor thrombus.
Further research interests include the molecular mechanisms underlying disease progression and therapeutic resistance. Han has published on the role of circRNA DOCK1 in modulating cell proliferation and apoptosis, and on the protooncogene TBL1XR1 as a potential cancer therapeutic target. Beyond oncology, Han has also explored the therapeutic potential of natural compounds, such as resveratrol, in alleviating pulmonary fibrosis by suppressing specific gene expression pathways.
With a scholarly output reflected in an h-index of 26 and over 2,600 citations across 153 publications, Han is recognized as a highly cited researcher. The lab maintains an active website, indicating ongoing research activities.
Metrics
- h-index: 26
- Publications: 141
- Citations: 2,259
Selected Publications
-
IRE1 signaling in osteoprogenitors augments β-catenin activity and physiologic bone accrual (2026)
Collaboration Network
Top Collaborators
- Transient Versus Sustained Phosphorylation and Nuclear Accumulation of ERKs Underlie Anti-Versus Pro-apoptotic Effects of Estrogens
- Estrogens attenuate oxidative stress and the differentiation and apoptosis of osteoblasts by DNA-binding-independent actions of the ERα
- Deletion of FoxO1, 3, and 4 in Osteoblast Progenitors Attenuates the Loss of Cancellous Bone Mass in a Mouse Model of Type 1 Diabetes
- Estrogens attenuate oxidative stress and the differentiation and apoptosis of osteoblasts by DNA-binding-independent actions of the ERα
- Deletion of FoxO1, 3, and 4 in Osteoblast Progenitors Attenuates the Loss of Cancellous Bone Mass in a Mouse Model of Type 1 Diabetes
- Estrogens attenuate oxidative stress and the differentiation and apoptosis of osteoblasts by DNA-binding-independent actions of the ERα
- Deletion of FoxO1, 3, and 4 in Osteoblast Progenitors Attenuates the Loss of Cancellous Bone Mass in a Mouse Model of Type 1 Diabetes
- Transient Versus Sustained Phosphorylation and Nuclear Accumulation of ERKs Underlie Anti-Versus Pro-apoptotic Effects of Estrogens
- Estrogens attenuate oxidative stress and the differentiation and apoptosis of osteoblasts by DNA-binding-independent actions of the ERα
- Deletion of FoxO1, 3, and 4 in Osteoblast Progenitors Attenuates the Loss of Cancellous Bone Mass in a Mouse Model of Type 1 Diabetes
- IRE1 signaling in osteoprogenitors augments β-catenin activity and physiologic bone accrual
- Estrogens attenuate oxidative stress and the differentiation and apoptosis of osteoblasts by DNA-binding-independent actions of the ERα
- Estrogens attenuate oxidative stress and the differentiation and apoptosis of osteoblasts by DNA-binding-independent actions of the ERα
- Estrogens attenuate oxidative stress and the differentiation and apoptosis of osteoblasts by DNA-binding-independent actions of the ERα
- Estrogens attenuate oxidative stress and the differentiation and apoptosis of osteoblasts by DNA-binding-independent actions of the ERα
- Estrogens attenuate oxidative stress and the differentiation and apoptosis of osteoblasts by DNA-binding-independent actions of the ERα
- Estrogens attenuate oxidative stress and the differentiation and apoptosis of osteoblasts by DNA-binding-independent actions of the ERα
- Transient Versus Sustained Phosphorylation and Nuclear Accumulation of ERKs Underlie Anti-Versus Pro-apoptotic Effects of Estrogens
- Transient Versus Sustained Phosphorylation and Nuclear Accumulation of ERKs Underlie Anti-Versus Pro-apoptotic Effects of Estrogens
- Transient Versus Sustained Phosphorylation and Nuclear Accumulation of ERKs Underlie Anti-Versus Pro-apoptotic Effects of Estrogens
- Transient Versus Sustained Phosphorylation and Nuclear Accumulation of ERKs Underlie Anti-Versus Pro-apoptotic Effects of Estrogens
Similar Researchers
Based on overlapping research topics